5 FREQUENTLY ASKED QUESTIONS ABOUT THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT

If you suffered losses in Integra LifeSciences stock contact Integra LifeSciences stock loss lawyer Timothy L. Miles 

INTRODUCTION TO THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT

​The Integra LifeSciences class action lawsuit​ seeks to represent purchasers or acquirers of Integra LifeSciences Holdings Corporation (NASDAQ: IART) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).  Captioned Pembroke Pines Firefighters & Police Officers Pension Fund v. Integra LifeSciences Holdings Corporation, No. 23-cv-20321 (D.N.J.), the Integra LifeSciences class action lawsuit charges Integra LifeSciences and certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.
​
If you suffered losses in Integra LifeSciences stock and wish to serve as lead plaintiff in the Integra LifeSciences class action lawsuit, please ​contact Integra LifeSciences Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 .or via e-mail at [email protected] or by submitting a contact form. Lead plaintiff motions for the Integra LifeSciences class action lawsuit must be filed with the court no later than November 13, 2023.

​​Read on for answers to five frequently asked questions about the Integra LifeSciences class action lawsuit

WHAT ARE THE ALLEGATIONS IN THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT?

​Integra LifeSciences develops regenerative tissue technologies and neurological solutions.  The IIntegra LifeSciences class action lawsuit alleges that on November 2, 2018, the U.S. Food and Drug Administration (“FDA”) issued a Notice of Inspectional Observations on Form 483 (the “2018 Form 483”) to put Integra LifeSciences on notice of quality systems and manufacturing conditions violations.  The complaint further alleges that on March 6, 2019, the FDA issued a warning letter (the “2019 Warning Letter”) to Integra LifeSciences further documenting the quality control and manufacturing problems at its Boston, Massachusetts facility (“Boston Facility”).  On November 12, 2021, the FDA issued another Form 483 (the “2021 Form 483”) for violations of good manufacturing practice requirements, the complaint further alleges. 

The Integra LifeSciences class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Integra LifeSciences failed to take sufficient measures to remediate the violations identified by the FDA in the 2018 Form 483, 2019 Warning Letter, and the 2021 Form 483; (ii) as a result of those deficiencies, since March 2018, all products manufactured in the Boston Facility had the potential for higher-than-permitted levels of endotoxin and would need to be recalled; and (iii) Integra LifeSciences was not making progress towards obtaining its premarket approval (“PMA”) indication for its product SurgiMend, in part, because the manufacturing site that would produce the PMA product was in continued violation of the FDA standards that Integra LifeSciences failed to rectify years after the initial notice of the violations.

The Integra LifeSciences class action lawsuit further alleges that on April 26, 2023, Integra LifeSciences disclosed that it had “[p]aused production at the Boston manufacturing site in March while pulling forward quality system upgrades project.”  As a result of the shutdown, Integra LifeSciences announced lowered operating margins for the quarter and flat revenue growth projection, the complaint alleges.  The Integra LifeSciences class action lawsuit that on this news, the price of Integra LifeSciences common stock fell nearly 8%.

​The Integra LifeSciences class action lawsuit further alleges that on May 23, 2023, Integra LifeSciences disclosed that “after consultation with the [FDA], [Integra LifeSciences] initiated a voluntary global recall of all products manufactured in its [Boston Facility]” that were “distributed between March 1, 2018 and May 22, 2023.”  The complaint further alleges that Integra LifeSciences revised its guidance for the second quarter of 2023, lowering its expectation for revenue by 6% and adjusted earnings per diluted share by 26%, and further revealed that Integra LifeSciences expects to take a $22 million impairment charge at the end of the second q`uarter of 2023 related to recalled inventory that would have to be written off.  The Integra Integra LifeSciences class action lawsuit alleges that on this news, the price of Integra LifeSciences common stock fell more than 20%.

WHAT IS THE LEAD PLAINTIFF PROCESS IN THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT?

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased and suffered losses in Integra LifeSciences stock to seek appointment as lead plaintiff in the Integra LifeSciences class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. 
​
​A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Integra LifeSciences stock and have further questions, contact Integra LifeSciences stock loss Lawyer Timothy L. Miles today who will fight to recover your damages in an Integra LifeSciences class action lawsuit if you suffered losses in Integra LifeSciences stock.

CAN A NON-U.S. INVESTOR SERVE AS LEAD PLAINTIFF IN THE INTEGRA LIFESCIENES CLASS ACTION LAWSUIT IF THEY SUFFERED LOSSES IN INTEGRA LIFESCIENCES?

​Yes, courts in the U.S. have consistently recognized that non-U.S. investors, many of whom have substantial holdings, are adequate lead plaintiffs and have the same right to move for lead plaintiffs as U.S. investors.  Thus, if a non-U.S. investor suffered losses in Integra LifeSciences stock​, they may move the Court to be appointed lead plaintiff in Integra LifeSciences class action lawsuit. 

IF I SUFFERED LOSSES IN INTEGRA LIFESCIENCES STOCK, WHAT ARE THE BENEFITS OF SERVING AS LEAD PLAINTIFF IN THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT?

Serving as a Lead Plaintiff in the Integra LifeSciences class action lawsuit has several advantages and important benefits including:

• A Lead Plaintiff is able to negotiate more competitive attorney fees and reduce other litigation costs by actively monitoring the class counsel.
• Lead Plaintiff has the benefit of being able to manage the litigation primarily by overseeing and monitoring the progress of the action and the efforts of counsel, and being able to review and comment on important filings and other documents pertaining to the prosecution of the action.
• There is no financial risk in serving as a Lead Plaintiff because Lead Counsel advances all costs and expenses incurred it the prosecution of the case and will be reimbursed only if there is a successful settlement or judgment recovery on behalf of the class.
• Lead Plaintiff has the benefit involved and active in all negotiations relating to any settlement.
• Lead Plaintiffs that continue owning the stock of the defendant will enjoy the long-term benefits from governance reform resulting from the litigation. 

Thus, there are numerous benefits and other advantages to serving as lead plaintiff in a class action against Integra LifeSciences​ if you suffered losses in Integra LifeSciences stock. 

IF I SUFFERED LOSSES IN SUFFERED LOSSES IN INTEGRA LIFESCIENCES STOCK, WHEN CAN I EXPECT TO RECEIVE MY PAYMENT IF THE INTEGRA LIFESCIENCES CLASS ACTION LAWSUIT SETTLES?

​If there is a settlement in the Integra LifeSciences class action lawsuit, you should receive a court-ordered Notice through the mail which will provide a date when the court will hold a final hearing to decide if it will approve the settlement in the Integra LifeSciences class action lawsuit. . If your address changed, you may also find lawsuits through sites such as Consumer Action and ClassAction.org along with instructions on how to submit a claim. The Notice will instruct you what you need to do to file a claim. In some class action settlements, you are automatically submitted and need to do nothing further. However, in others, you may be required to submit more information to proceed such as documentation proving your purchase, such as a receipt or brokerage slip or other evidence that you bought or sold Integra LifeSciences stock during the class period and suffered losses in Integra LifeSciences stock.
 
The court will hold a final hearing in the Integra LifeSciences class action lawsuit on a date provided in the Notice to decide whether to finally approve the settlement. If the Court finally approves the settlement, and there are no objections or appeals, settlement payments will be mailed to all Participating Class Members within a few months. However, if there are objections or appeals, resolving them can take a significant amount of time, perhaps more than a year to resolve the Integra LifeSciences class action lawsuit. ​

CONTACT AN INTEGRA LIFESCIENCES STOCK LOSS LAWYER TODAY IF YOU SUFFERED LOSSES IN INTEGRA LIFESCIENCES STOCK ABOUT AN INTEGRA LIFESCIENCESCLASS ACTION LAWSUIT

​If you suffered losses in Integra LifeSciences stock, contact Integra LifeSciences stock loss lawyer Timothy L. Miles today for a free case evaluation about an Integra LifeSciences class action lawsuit. Call today and see what an Integra LifeSciences stock loss lawyer can do for you if you suffered losses in Integra LifeSciences stock.

LifeSciences stock loss lawyer Timothy L. Miles

Nashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors, shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, 6Class Action:  Class Action: Top National Trial Lawyers, National Trial Lawyers Association (2023), a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM  (2019-2022); America's Most Honored Lawyers 2020; Top 1% by America's Most Honored (2020-2022).  Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more.  Please visit our website or call for free anytime.

CONTACT                                                      
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr., #247
Brentwood, TN 37027
Phone: (855) 846-6529